Dilution is a major problem with this company and a major reason for decline in the stock price over the last 8 months.
If they don't get their FDA approval by end of year, why did they pay out another 12.5M shares to Novalere? Also, if they approval doesn't happen, what about the 12.5M shares? Is the company going to get them back?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.